ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000719

The impact of depressive symptoms in early Parkinson disease

Identifieur interne : 000719 ( PascalFrancis/Corpus ); précédent : 000718; suivant : 000720

The impact of depressive symptoms in early Parkinson disease

Auteurs : B. Ravina ; R. Camicioli ; P. G. Como ; L. Marsh ; J. Jankovic ; D. Weintraub ; J. Elm

Source :

Neurology [ 0028-3878 ] ; 2007.

RBID : Pascal:07-0388459

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Etat dépressif, Parkinson maladie.

English descriptors

KwdEn :
- Depression, Nervous system diseases, Parkinson disease.

Abstract

Background: Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD. Methods: We administered the 15-item Geriatric Depression Scale (GDS-15) as part of two NIH-sponsored phase II clinical trials in PD, enrolling 413 early, untreated PD subjects. We used linear mixed models to examine the relationship of depressive symptoms, measured by the GDS-15, with motor function and activities of daily living (ADLs), as measured by the Unified PD Rating Scale (UPDRS). A time-dependent Cox model was used to examine the effect of demographic and clinical outcome measures as predictors of investigator-determined time to need for symptomatic therapy for PD. Results: A total of 114 (27.6%) subjects screened positive for depression during the average 14.6 months of follow-up. Forty percent of these subjects were neither treated with antidepressants nor referred for further psychiatric evaluation. Depression, as assessed by the GDS-15, was a significant predictor of more impairment in ADLs (p < 0.0001) and increased need for symptomatic therapy of PD (hazard ratio = 1.86; 95% Cl 1.29, 2.68). Conclusions: Clinically important depressive symptoms are common in early Parkinson disease (PD), but are often not treated. Depressive symptoms are an important contributor to disability and the decision to start symptomatic therapy for motor-related impairment in early PD, highlighting the broad importance of identifying and treating depression in this population.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0028-3878`
A02	`01`			`@0 NEURAI`
A03		`1`		`@0 Neurology`
A05				`@2 69`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 The impact of depressive symptoms in early Parkinson disease`
A11	`01`	`1`		`@1 RAVINA (B.)`
A11	`02`	`1`		`@1 CAMICIOLI (R.)`
A11	`03`	`1`		`@1 COMO (P. G.)`
A11	`04`	`1`		`@1 MARSH (L.)`
A11	`05`	`1`		`@1 JANKOVIC (J.)`
A11	`06`	`1`		`@1 WEINTRAUB (D.)`
A11	`07`	`1`		`@1 ELM (J.)`
A14	`01`			`@1 Department of Neurology University of Rochester School of Medicine and Dentistry @2 NY @3 USA @Z 1 aut. @Z 3 aut.`
A14	`02`			`@1 Department of Neurology University of Alberta @2 Edmonton @3 CAN @Z 2 aut.`
A14	`03`			`@1 Departments of Psychiatry and Neurology Johns Hopkins University @2 Baltimore, MD @3 USA @Z 4 aut.`
A14	`04`			`@1 Department of Neurology Baylor University @2 Houston, TX @3 USA @Z 5 aut.`
A14	`05`			`@1 Departments of Psychiatry and Neurology University of Pennsylvania @2 Philadelphia @3 USA @Z 6 aut.`
A14	`06`			`@1 Department of Biostatistics Medical University of South Carolina @2 Charleston @3 USA @Z 7 aut.`
A20				`@1 342-347`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6345 @5 354000146491570040`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 31 ref.`
A47	`01`	`1`		`@0 07-0388459`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background: Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD. Methods: We administered the 15-item Geriatric Depression Scale (GDS-15) as part of two NIH-sponsored phase II clinical trials in PD, enrolling 413 early, untreated PD subjects. We used linear mixed models to examine the relationship of depressive symptoms, measured by the GDS-15, with motor function and activities of daily living (ADLs), as measured by the Unified PD Rating Scale (UPDRS). A time-dependent Cox model was used to examine the effect of demographic and clinical outcome measures as predictors of investigator-determined time to need for symptomatic therapy for PD. Results: A total of 114 (27.6%) subjects screened positive for depression during the average 14.6 months of follow-up. Forty percent of these subjects were neither treated with antidepressants nor referred for further psychiatric evaluation. Depression, as assessed by the GDS-15, was a significant predictor of more impairment in ADLs (p < 0.0001) and increased need for symptomatic therapy of PD (hazard ratio = 1.86; 95% Cl 1.29, 2.68). Conclusions: Clinically important depressive symptoms are common in early Parkinson disease (PD), but are often not treated. Depressive symptoms are an important contributor to disability and the decision to start symptomatic therapy for motor-related impairment in early PD, highlighting the broad importance of identifying and treating depression in this population.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Etat dépressif @5 02`
C03	`02`	`X`	`ENG`	`@0 Depression @5 02`
C03	`02`	`X`	`SPA`	`@0 Estado depresivo @5 02`
C03	`03`	`X`	`FRE`	`@0 Parkinson maladie @5 03`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @5 03`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @5 03`
C07	`01`	`X`	`FRE`	`@0 Trouble humeur @5 37`
C07	`01`	`X`	`ENG`	`@0 Mood disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Trastorno humor @5 37`
C07	`02`	`X`	`FRE`	`@0 Encéphale pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
N21				`@1 253`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 07-0388459 INIST
ET :	The impact of depressive symptoms in early Parkinson disease
AU :	RAVINA (B.); CAMICIOLI (R.); COMO (P. G.); MARSH (L.); JANKOVIC (J.); WEINTRAUB (D.); ELM (J.)
AF :	Department of Neurology University of Rochester School of Medicine and Dentistry/NY/Etats-Unis (1 aut., 3 aut.); Department of Neurology University of Alberta/Edmonton/Canada (2 aut.); Departments of Psychiatry and Neurology Johns Hopkins University/Baltimore, MD/Etats-Unis (4 aut.); Department of Neurology Baylor University/Houston, TX/Etats-Unis (5 aut.); Departments of Psychiatry and Neurology University of Pennsylvania/Philadelphia/Etats-Unis (6 aut.); Department of Biostatistics Medical University of South Carolina/Charleston/Etats-Unis (7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 2007; Vol. 69; No. 4; Pp. 342-347; Bibl. 31 ref.
LA :	Anglais
EA :	Background: Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD. Methods: We administered the 15-item Geriatric Depression Scale (GDS-15) as part of two NIH-sponsored phase II clinical trials in PD, enrolling 413 early, untreated PD subjects. We used linear mixed models to examine the relationship of depressive symptoms, measured by the GDS-15, with motor function and activities of daily living (ADLs), as measured by the Unified PD Rating Scale (UPDRS). A time-dependent Cox model was used to examine the effect of demographic and clinical outcome measures as predictors of investigator-determined time to need for symptomatic therapy for PD. Results: A total of 114 (27.6%) subjects screened positive for depression during the average 14.6 months of follow-up. Forty percent of these subjects were neither treated with antidepressants nor referred for further psychiatric evaluation. Depression, as assessed by the GDS-15, was a significant predictor of more impairment in ADLs (p < 0.0001) and increased need for symptomatic therapy of PD (hazard ratio = 1.86; 95% Cl 1.29, 2.68). Conclusions: Clinically important depressive symptoms are common in early Parkinson disease (PD), but are often not treated. Depressive symptoms are an important contributor to disability and the decision to start symptomatic therapy for motor-related impairment in early PD, highlighting the broad importance of identifying and treating depression in this population.
CC :	002B17; 002B17G; 002B17A03
FD :	Système nerveux pathologie; Etat dépressif; Parkinson maladie
FG :	Trouble humeur; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie
ED :	Nervous system diseases; Depression; Parkinson disease
EG :	Mood disorder; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Sistema nervioso patología; Estado depresivo; Parkinson enfermedad
LO :	INIST-6345.354000146491570040
ID :	07-0388459

Links to Exploration step

Pascal:07-0388459

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The impact of depressive symptoms in early Parkinson disease</title>
<author><name sortKey="Ravina, B" sort="Ravina, B" uniqKey="Ravina B" first="B." last="Ravina">B. Ravina</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology University of Rochester School of Medicine and Dentistry</s1>
<s2>NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Camicioli, R" sort="Camicioli, R" uniqKey="Camicioli R" first="R." last="Camicioli">R. Camicioli</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Como, P G" sort="Como, P G" uniqKey="Como P" first="P. G." last="Como">P. G. Como</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology University of Rochester School of Medicine and Dentistry</s1>
<s2>NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, L" sort="Marsh, L" uniqKey="Marsh L" first="L." last="Marsh">L. Marsh</name>
<affiliation><inist:fA14 i1="03"><s1>Departments of Psychiatry and Neurology Johns Hopkins University</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J." last="Jankovic">J. Jankovic</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology Baylor University</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D." last="Weintraub">D. Weintraub</name>
<affiliation><inist:fA14 i1="05"><s1>Departments of Psychiatry and Neurology University of Pennsylvania</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Elm, J" sort="Elm, J" uniqKey="Elm J" first="J." last="Elm">J. Elm</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Biostatistics Medical University of South Carolina</s1>
<s2>Charleston</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0388459</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0388459 INIST</idno>
<idno type="RBID">Pascal:07-0388459</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000719</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The impact of depressive symptoms in early Parkinson disease</title>
<author><name sortKey="Ravina, B" sort="Ravina, B" uniqKey="Ravina B" first="B." last="Ravina">B. Ravina</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology University of Rochester School of Medicine and Dentistry</s1>
<s2>NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Camicioli, R" sort="Camicioli, R" uniqKey="Camicioli R" first="R." last="Camicioli">R. Camicioli</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Como, P G" sort="Como, P G" uniqKey="Como P" first="P. G." last="Como">P. G. Como</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology University of Rochester School of Medicine and Dentistry</s1>
<s2>NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, L" sort="Marsh, L" uniqKey="Marsh L" first="L." last="Marsh">L. Marsh</name>
<affiliation><inist:fA14 i1="03"><s1>Departments of Psychiatry and Neurology Johns Hopkins University</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J." last="Jankovic">J. Jankovic</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology Baylor University</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D." last="Weintraub">D. Weintraub</name>
<affiliation><inist:fA14 i1="05"><s1>Departments of Psychiatry and Neurology University of Pennsylvania</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Elm, J" sort="Elm, J" uniqKey="Elm J" first="J." last="Elm">J. Elm</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Biostatistics Medical University of South Carolina</s1>
<s2>Charleston</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Depression</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Etat dépressif</term>
<term>Parkinson maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD. Methods: We administered the 15-item Geriatric Depression Scale (GDS-15) as part of two NIH-sponsored phase II clinical trials in PD, enrolling 413 early, untreated PD subjects. We used linear mixed models to examine the relationship of depressive symptoms, measured by the GDS-15, with motor function and activities of daily living (ADLs), as measured by the Unified PD Rating Scale (UPDRS). A time-dependent Cox model was used to examine the effect of demographic and clinical outcome measures as predictors of investigator-determined time to need for symptomatic therapy for PD. Results: A total of 114 (27.6%) subjects screened positive for depression during the average 14.6 months of follow-up. Forty percent of these subjects were neither treated with antidepressants nor referred for further psychiatric evaluation. Depression, as assessed by the GDS-15, was a significant predictor of more impairment in ADLs (p < 0.0001) and increased need for symptomatic therapy of PD (hazard ratio = 1.86; 95% Cl 1.29, 2.68). Conclusions: Clinically important depressive symptoms are common in early Parkinson disease (PD), but are often not treated. Depressive symptoms are an important contributor to disability and the decision to start symptomatic therapy for motor-related impairment in early PD, highlighting the broad importance of identifying and treating depression in this population.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3878</s0>
</fA01>
<fA02 i1="01"><s0>NEURAI</s0>
</fA02>
<fA03 i2="1"><s0>Neurology</s0>
</fA03>
<fA05><s2>69</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>The impact of depressive symptoms in early Parkinson disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RAVINA (B.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CAMICIOLI (R.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>COMO (P. G.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MARSH (L.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>JANKOVIC (J.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>WEINTRAUB (D.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ELM (J.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology University of Rochester School of Medicine and Dentistry</s1>
<s2>NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Departments of Psychiatry and Neurology Johns Hopkins University</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology Baylor University</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Departments of Psychiatry and Neurology University of Pennsylvania</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Biostatistics Medical University of South Carolina</s1>
<s2>Charleston</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>342-347</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6345</s2>
<s5>354000146491570040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>31 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0388459</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD. Methods: We administered the 15-item Geriatric Depression Scale (GDS-15) as part of two NIH-sponsored phase II clinical trials in PD, enrolling 413 early, untreated PD subjects. We used linear mixed models to examine the relationship of depressive symptoms, measured by the GDS-15, with motor function and activities of daily living (ADLs), as measured by the Unified PD Rating Scale (UPDRS). A time-dependent Cox model was used to examine the effect of demographic and clinical outcome measures as predictors of investigator-determined time to need for symptomatic therapy for PD. Results: A total of 114 (27.6%) subjects screened positive for depression during the average 14.6 months of follow-up. Forty percent of these subjects were neither treated with antidepressants nor referred for further psychiatric evaluation. Depression, as assessed by the GDS-15, was a significant predictor of more impairment in ADLs (p < 0.0001) and increased need for symptomatic therapy of PD (hazard ratio = 1.86; 95% Cl 1.29, 2.68). Conclusions: Clinically important depressive symptoms are common in early Parkinson disease (PD), but are often not treated. Depressive symptoms are an important contributor to disability and the decision to start symptomatic therapy for motor-related impairment in early PD, highlighting the broad importance of identifying and treating depression in this population.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Depression</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>03</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Trouble humeur</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>253</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 07-0388459 INIST</NO>
<ET>The impact of depressive symptoms in early Parkinson disease</ET>
<AU>RAVINA (B.); CAMICIOLI (R.); COMO (P. G.); MARSH (L.); JANKOVIC (J.); WEINTRAUB (D.); ELM (J.)</AU>
<AF>Department of Neurology University of Rochester School of Medicine and Dentistry/NY/Etats-Unis (1 aut., 3 aut.); Department of Neurology University of Alberta/Edmonton/Canada (2 aut.); Departments of Psychiatry and Neurology Johns Hopkins University/Baltimore, MD/Etats-Unis (4 aut.); Department of Neurology Baylor University/Houston, TX/Etats-Unis (5 aut.); Departments of Psychiatry and Neurology University of Pennsylvania/Philadelphia/Etats-Unis (6 aut.); Department of Biostatistics Medical University of South Carolina/Charleston/Etats-Unis (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 2007; Vol. 69; No. 4; Pp. 342-347; Bibl. 31 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD. Methods: We administered the 15-item Geriatric Depression Scale (GDS-15) as part of two NIH-sponsored phase II clinical trials in PD, enrolling 413 early, untreated PD subjects. We used linear mixed models to examine the relationship of depressive symptoms, measured by the GDS-15, with motor function and activities of daily living (ADLs), as measured by the Unified PD Rating Scale (UPDRS). A time-dependent Cox model was used to examine the effect of demographic and clinical outcome measures as predictors of investigator-determined time to need for symptomatic therapy for PD. Results: A total of 114 (27.6%) subjects screened positive for depression during the average 14.6 months of follow-up. Forty percent of these subjects were neither treated with antidepressants nor referred for further psychiatric evaluation. Depression, as assessed by the GDS-15, was a significant predictor of more impairment in ADLs (p < 0.0001) and increased need for symptomatic therapy of PD (hazard ratio = 1.86; 95% Cl 1.29, 2.68). Conclusions: Clinically important depressive symptoms are common in early Parkinson disease (PD), but are often not treated. Depressive symptoms are an important contributor to disability and the decision to start symptomatic therapy for motor-related impairment in early PD, highlighting the broad importance of identifying and treating depression in this population.</EA>
<CC>002B17; 002B17G; 002B17A03</CC>
<FD>Système nerveux pathologie; Etat dépressif; Parkinson maladie</FD>
<FG>Trouble humeur; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie</FG>
<ED>Nervous system diseases; Depression; Parkinson disease</ED>
<EG>Mood disorder; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Estado depresivo; Parkinson enfermedad</SD>
<LO>INIST-6345.354000146491570040</LO>
<ID>07-0388459</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000719 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000719 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:07-0388459
   |texte=   The impact of depressive symptoms in early Parkinson disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

The impact of depressive symptoms in early Parkinson disease

The impact of depressive symptoms in early Parkinson disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri